149 related articles for article (PubMed ID: 33875622)
21. Pathologic tumor response to neoadjuvant therapy in borderline resectable pancreatic cancer.
Peng JS; Wey J; Chalikonda S; Allende DS; Walsh RM; Morris-Stiff G
Hepatobiliary Pancreat Dis Int; 2019 Aug; 18(4):373-378. PubMed ID: 31176601
[TBL] [Abstract][Full Text] [Related]
22. Prognostic value of major pathological response following neoadjuvant therapy for non resectable pancreatic ductal adenocarcinoma.
Bao QR; Frigerio I; Tripepi M; Marletta S; Martignoni G; Giardino A; Regi P; Scopelliti F; Allegrini V; Girelli R; Pucciarelli S; Spolverato G; Butturini G
Pancreatology; 2023 Apr; 23(3):266-274. PubMed ID: 36841686
[TBL] [Abstract][Full Text] [Related]
23. A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma.
Hosein PJ; Macintyre J; Kawamura C; Maldonado JC; Ernani V; Loaiza-Bonilla A; Narayanan G; Ribeiro A; Portelance L; Merchan JR; Levi JU; Rocha-Lima CM
BMC Cancer; 2012 May; 12():199. PubMed ID: 22642850
[TBL] [Abstract][Full Text] [Related]
24. Impact of neoadjuvant chemotherapy and stereotactic body radiation therapy (SBRT) on R0 resection rate for borderline resectable and locally advanced pancreatic cancer.
Zakem SJ; Mueller AC; Meguid C; Torphy RJ; Holt DE; Schefter T; Messersmith WA; McCarter MD; Del Chiaro M; Schulick RD; Goodman KA
HPB (Oxford); 2021 Jul; 23(7):1072-1083. PubMed ID: 33277184
[TBL] [Abstract][Full Text] [Related]
25. The predictive value of histological tumor regression grading (TRG) for therapeutic evaluation in locally advanced esophageal carcinoma treated with neoadjuvant chemotherapy.
Guo K; Cai L; Zhang Y; Zhu JF; Rong TH; Lin P; Hao CL; Wang WP; Li Z; Zhang LJ
Chin J Cancer; 2012 Aug; 31(8):399-408. PubMed ID: 22572013
[TBL] [Abstract][Full Text] [Related]
26. Assessment of pathologic response and long-term outcome in locally advanced breast cancers after neoadjuvant chemotherapy: comparison of pathologic classification systems.
Choi M; Park YH; Ahn JS; Im YH; Nam SJ; Cho SY; Cho EY
Breast Cancer Res Treat; 2016 Dec; 160(3):475-489. PubMed ID: 27730423
[TBL] [Abstract][Full Text] [Related]
27. Neoadjuvant radiation followed by resection versus upfront resection for locally advanced pancreatic cancer patients: a propensity score matched analysis.
Chen X; Liu G; Wang K; Chen G; Sun J
Oncotarget; 2017 Jul; 8(29):47831-47840. PubMed ID: 28599299
[TBL] [Abstract][Full Text] [Related]
28. Adjuvant Chemotherapy Is Not Guided by Pathologic Treatment Effect After Neoadjuvant Chemotherapy in Pancreatic Cancer.
Gleeson EM; Leigh N; Golas BJ; Magge D; Sarpel U; Hiotis SP; Labow DM; Pintova S; Cohen NA
Pancreas; 2021 Sep; 50(8):1163-1168. PubMed ID: 34714279
[TBL] [Abstract][Full Text] [Related]
29. Extended neoadjuvant chemotherapy for borderline resectable pancreatic cancer demonstrates promising postoperative outcomes and survival.
Rose JB; Rocha FG; Alseidi A; Biehl T; Moonka R; Ryan JA; Lin B; Picozzi V; Helton S
Ann Surg Oncol; 2014 May; 21(5):1530-7. PubMed ID: 24473642
[TBL] [Abstract][Full Text] [Related]
30. Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX.
Choi YH; Lee SH; You MS; Shin BS; Paik WH; Ryu JK; Kim YT; Kwon W; Jang JY; Kim SW
Gut Liver; 2021 Mar; 15(2):315-323. PubMed ID: 32235008
[TBL] [Abstract][Full Text] [Related]
31. Regression grading in neoadjuvant treated pancreatic cancer: an interobserver study.
N Kalimuthu S; Serra S; Dhani N; Hafezi-Bakhtiari S; Szentgyorgyi E; Vajpeyi R; Chetty R
J Clin Pathol; 2017 Mar; 70(3):237-243. PubMed ID: 27681847
[TBL] [Abstract][Full Text] [Related]
32. CT evaluation after neoadjuvant FOLFIRINOX chemotherapy for borderline and locally advanced pancreatic adenocarcinoma.
Wagner M; Antunes C; Pietrasz D; Cassinotto C; Zappa M; Sa Cunha A; Lucidarme O; Bachet JB
Eur Radiol; 2017 Jul; 27(7):3104-3116. PubMed ID: 27896469
[TBL] [Abstract][Full Text] [Related]
33. Management of borderline and locally advanced pancreatic cancer: where do we stand?
He J; Page AJ; Weiss M; Wolfgang CL; Herman JM; Pawlik TM
World J Gastroenterol; 2014 Mar; 20(9):2255-66. PubMed ID: 24605025
[TBL] [Abstract][Full Text] [Related]
34. Morphologic changes associated with neoadjuvant-treated pancreatic ductal adenocarcinoma and comparison of two tumor regression grading systems.
Vazzano J; Frankel WL; Wolfe AR; Williams TM; Chen W
Hum Pathol; 2021 Mar; 109():1-11. PubMed ID: 33245985
[TBL] [Abstract][Full Text] [Related]
35. How to approach pancreatic cancer after neoadjuvant treatment: assessment of resectability using multidetector CT and tumor markers.
Jeon SK; Lee JM; Lee ES; Yu MH; Joo I; Yoon JH; Jang JY; Lee KB; Lee SH
Eur Radiol; 2022 Jan; 32(1):56-66. PubMed ID: 34170366
[TBL] [Abstract][Full Text] [Related]
36. Complete pathological response following neoadjuvant FOLFIRINOX in borderline resectable pancreatic cancer - a case report and review.
Gostimir M; Bennett S; Moyana T; Sekhon H; Martel G
BMC Cancer; 2016 Oct; 16(1):786. PubMed ID: 27724927
[TBL] [Abstract][Full Text] [Related]
37. Important CT and histopathological findings for recurrence and overall survival in patients with pancreatic ductal adenocarcinoma who underwent surgery after neoadjuvant FOLFIRINOX.
Park SJ; Kim JH; Joo I; Lee KB; Han JK
Eur Radiol; 2021 Jun; 31(6):3616-3626. PubMed ID: 33201279
[TBL] [Abstract][Full Text] [Related]
38. Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy.
Schmocker RK; Delitto D; Wright MJ; Ding D; Cameron JL; Lafaro KJ; Burns WR; Wolfgang CL; Burkhart RA; He J
J Am Coll Surg; 2021 Apr; 232(4):405-413. PubMed ID: 33338577
[TBL] [Abstract][Full Text] [Related]
39. Reproducibility and prognostic significance of area of residual tumor (ART) in post-neoadjuvant resections of pancreatic ductal adenocarcinoma.
Kameyama A; Ye J; Shimomura A; Yokohira M; Nakano-Narusawa Y; Yamakawa K; Mukai Y; Sanomura T; Okuyama H; Miyatake N; Furihata M; Tanaka C; Kitazawa R; Bando Y; Suemitsu Y; Kojima M; Mino-Kenudson M; Suzuki Y; Okano K; Matsuda Y
Pancreatology; 2021 Dec; 21(8):1506-1515. PubMed ID: 34563448
[TBL] [Abstract][Full Text] [Related]
40. Surgery Improves Survival After Neoadjuvant Therapy for Borderline and Locally Advanced Pancreatic Cancer: A Single Institution Experience.
Rangelova E; Wefer A; Persson S; Valente R; Tanaka K; Orsini N; Segersvärd R; Arnelo U; Del Chiaro M
Ann Surg; 2021 Mar; 273(3):579-586. PubMed ID: 30946073
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
